Crossmark

Addressing low-value pharmacological prescribing in primary prevention of CVD through a structured evidence-based and theory-informed process for the design and testing of de-implementation strategies: the DE-imFAR study

Crossref DOI link: https://doi.org/10.1186/s13012-020-0966-3

Published Online: 2020-01-22

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sanchez, Alvaro https://orcid.org/0000-0001-8600-2119
Pijoan, Jose Ignacio

Pablo, Susana

Mediavilla, Marta

de Rozas, Rita Sainz

Lekue, Itxasne

Gonzalez-Larragan, Susana

Lantaron, Gaspar

Argote, Jon

García-Álvarez, Arturo

Latorre, Pedro Maria

Helfrich, Christian D.

Grandes, Gonzalo
Funding

Funding for this research was provided by:

Health Department, Eusko Jaurlaritza (2018111085)

Instituto de Salud Carlos III (RD16/0007/0002)
License Information

Text and Data Mining valid from 2020-01-22

Version of Record valid from 2020-01-22
More Information

Article History

Received: 13 December 2019

Accepted: 6 January 2020

First Online: 22 January 2020

Ethics approval and consent to participate

: The research protocol has been approved by the Basque Country Clinical Research Ethics Committee (Ref: PI2019102, approved on 10/04/2019). The Primary Care Research Unit of Bizkaia is explicitly authorized by the Healthcare Management of the Basque Health System to extract and use data from the electronic health records for research purposes.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below